Senior Correspondent, London
Ben's Feed
Jan 16, 2015
Jan 16, 2015
Jan 15, 2015
Jan 15, 2015

Conflict trumps economy as top risk to world in Davos survey

LONDON (Reuters) – The risk of international conflict is now the biggest threat facing countries and businesses in the coming decade, trumping concerns about the economy, the World Economic Forum said on Thursday.

The group’s annual assessment of global hazards sets the scene for its meeting in Davos next week, although it is based on responses received some months ago. It is the first time the survey has headlined conflict as the top risk, reflecting an increasingly dangerous world.

Jan 15, 2015
Jan 14, 2015
Jan 14, 2015

AstraZeneca heart drug hits goal in major clinical trial

LONDON (Reuters) – AstraZeneca’s blood-thinning drug Brilinta cut the risk of death or heart attack in patients with a history of previous attacks, according to a major clinical trial that will boost hopes for the product.

Using Brilinta in this patient population could more than double the number of people eligible for the medicine, which the company has predicted could eventually generate sales of $3.5 billion a year.

Jan 13, 2015
Jan 12, 2015

J&J strikes Alzheimer’s research deal with Swiss firm AC Immune

LONDON/ZURICH (Reuters) – Johnson & Johnson boosted its research efforts into battling Alzheimer’s on Monday, striking a deal potentially worth more than $500 million to develop anti-tau vaccines with Swiss biotech firm AC Immune.

Tau is a protein known for forming twisted fibers inside brain cells and is linked to cell death. It is one of two abnormal proteins tied to the memory-robbing disease. The other is beta amyloid.

Jan 12, 2015
    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben